ESMO 2023 – Amgen’s Steap1 project spurs cautious optimism
But toxicity will be closely watched in future trials.
But toxicity will be closely watched in future trials.
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
But late-breaking data raise questions about lack of a dose response.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.